ERBB2 and breast carcinoma: In this study, breast cancer cell lines with combinations of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) biomarkers as well as triple negative cell lines (Table 1) were interrogated for CD47 expression.